Echocardiography referral criteria for valvular heart disease
Transthoracic echocardiography is the gatekeeper of every valvular heart disease workup.
Before a surgeon sees the patient, before the Heart Team convenes, before a transcatheter valve gets measured on a CT workstation, a probe sits on the chest wall and produces the numbers that drive the entire decision tree. Both the 2020 ACC/AHA guideline and the 2025 ESC/EACTS update place TTE at the front of the diagnostic pathway. The question is not whether to order it. The question is what to look for, which thresholds matter, and when the imaging stops being diagnostic.
This is the atlas for that question. The criteria below translate the major guideline thresholds into a working checklist: when to trigger TTE, how to grade what the probe shows, when to escalate, and where the Heart Team now sits in the pathway.
TTE as the First-Line Imaging Modality
The 2020 ACC/AHA guideline and the 2025 ESC/EACTS update converge on a single starting point. TTE is the recommended first-line test for any patient with suspected or established valvular heart disease. The probe must answer four questions in a single exam. Confirm the lesion exists. Characterize the anatomy. Quantify the severity. Assess the ventricular response.
Confirm anatomy means identifying the affected valve, the lesion morphology (rheumatic, calcific, prolapse, endocarditic), and any associated abnormalities — chamber dilation, wall motion changes, pulmonary pressures. Severity grading is where the quantitative thresholds come in. Ventricular response looks at LVEF, chamber dimensions, and — depending on the valve — right ventricular function and pulmonary pressures.
Clinical triggers for the initial TTE order:
- A newly detected murmur with symptoms (dyspnea, chest pain, syncope, declining exercise capacity).
- A newly detected murmur in an asymptomatic patient where structural disease is suspected.
- Known VHD requiring surveillance — timing based on severity staging and lesion type.
- A change in clinical status in a patient with known VHD.
- Pre-procedural assessment before cardiac or non-cardiac surgery when valve disease is suspected.
What the TTE cannot do: replace auscultation. Auscultation triggers the workup. TTE confirms and quantifies it. A benign exam does not rule out progressive disease, and a symptomatic patient with a new murmur needs the probe regardless of how the exam sounds.
TTE is the gatekeeper. Every downstream decision — timing of surgery, escalation to advanced imaging, referral to a valve centre — depends on what the transthoracic probe shows first.
Quantifying Severity: The Numbers That Matter
Severity grading lives or dies on quantitative thresholds. The guidelines codify them, and they should sit next to the echo machine on a reference card, not in a binder no one opens. Three valve lesions cover the bulk of the load.
Aortic stenosis grading requires the full Level I parameter set: maximum velocity, mean pressure gradient, and aortic valve area. Severe AS is defined by a peak velocity ≥ 4.0 m/s, a mean gradient ≥ 40 mmHg, or an aortic valve area ≤ 1.0 cm² (indexed AVA ≤ 0.6 cm²/m²). Low-flow, low-gradient AS — reduced LVEF with low gradient but severe valve area — requires dobutamine stress echocardiography to differentiate true severe from pseudo-severe disease. These are integrated findings.
Aortic regurgitation uses a different parameter set: regurgitant volume, regurgitant fraction, effective regurgitant orifice area, vena contracta width, and pressure half-time of the AR jet. Severe AR is defined by regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, EROA ≥ 0.30 cm², vena contracta > 6 mm, or PHT < 200 ms. Again, integrated findings — not a single cut-point.
Mitral regurgitation has its own scale. For severe organic MR, the quantitative parameters are vena contracta width ≥ 7 mm (or > 8 mm on biplane), regurgitant volume ≥ 60 mL, regurgitant fraction ≥ 50%, and EROA ≥ 0.40 cm². Secondary MR, where the mechanism is ventricular rather than valvular, uses different thresholds and a different therapeutic pathway.
A single cutoff won't catch severe aortic stenosis. Velocity, mean gradient, and valve area have to be read together — discordance between them is itself a clinical signal.
Severity Thresholds at a Glance
| Lesion | Severe Threshold | Key Parameters |
|---|---|---|
| Aortic stenosis | Peak velocity ≥ 4.0 m/s, mean gradient ≥ 40 mmHg, AVA ≤ 1.0 cm² | All three Level I parameters required |
| Aortic regurgitation | Reg vol ≥ 60 mL, RF ≥ 50%, EROA ≥ 0.30 cm², VC > 6 mm | Multiple parameters, integrated |
| Organic mitral regurgitation | VC ≥ 7 mm (>8 mm biplane), reg vol ≥ 60 mL, EROA ≥ 0.40 cm² | Quantitative echo |
| Mitral stenosis | MVA ≤ 1.5 cm², mean gradient ≥ 5–10 mmHg | Planimetry or pressure half-time |
The table is a working reference, not a diagnostic device. Each lesion has integration rules — low-flow states, pressure recovery, body surface area indexing — that change the read on these numbers. The reference card gets you to the right zone. The full echo report makes the call.
Intervention Triggers: When Numbers Meet Symptoms
Severe by echo is not the same as severe by indication. Intervention triggers for chronic severe valve disease combine severity grading with two clinical signals: symptoms and ventricular response.
In asymptomatic chronic severe aortic regurgitation, surgery is triggered when LVEF drops below 55%. The cutoff is hard. Above 55% and asymptomatic, the patient is followed on serial echo — typically every 6–12 months depending on measurement stability. Below 55% on a confirmatory study, the patient moves toward surgical evaluation regardless of symptom status. Additional triggers include indexed LV end-systolic dimension > 50 mm (>25 mm/m²) and onset of symptoms in previously asymptomatic severe AR.
For severe aortic stenosis, intervention is triggered once symptoms develop (exertional dyspnea, angina, syncope, heart failure) or once LVEF falls below 50% in asymptomatic severe AS. A peak velocity ≥ 5.0 m/s or a mean gradient ≥ 60 mmHg in an asymptomatic patient is considered severe enough to consider intervention in the 2025 ESC/EACTS update, depending on Heart Team assessment.
For severe organic MR, intervention is triggered by symptoms, LVEF 30–60%, or LV end-systolic dimension ≥ 40 mm. Asymptomatic patients with preserved LVEF and normal LV dimensions are followed with serial echo; intervention timing is reassessed at each cycle.
These triggers are binary in form: refer or don't refer. In practice, the borderline patient with severe echo findings, mild symptoms, and borderline LVEF sits in a gray zone. That gray zone is what the Heart Team is built to resolve.
Discordant Findings: Escalating the Imaging Pathway
TTE is the gatekeeper, but not the final word. When the transthoracic image quality is poor, when the clinical picture and the echo numbers disagree, or when the anatomical detail required for procedural planning isn't there, escalation is mandatory.
The three escalation pathways are TEE, cardiac CT, and cardiac MRI. Each has a defined role.
Transesophageal echocardiography provides higher-resolution imaging of valve anatomy, particularly for mitral valve pathology, prosthetic valve dysfunction, and infective endocarditis. TEE is indicated when TTE is non-diagnostic for suspected prosthetic valve endocarditis, when MR mechanism is unclear (especially for surgical planning), and when intracardiac masses or thrombus are suspected.
Cardiac CT has become central to pre-procedural planning for transcatheter aortic valve replacement and is increasingly used for pre-procedural planning for transcatheter mitral and tricuspid interventions. CT provides annular sizing, vascular access assessment, and prediction of paravalvular leak risk. It is the standard second test for TAVR planning once TTE confirms severe AS.
Cardiac MRI is the reference standard for quantifying regurgitant volume in AR and MR when echo is discordant with clinical findings. It is also used for myocardial tissue characterization in cases where valve lesion and underlying ventricular disease both need characterization.
When TTE and the clinical picture disagree, don't repeat the TTE. Escalate. TEE for anatomy, CT for procedural planning, MRI for quantification when echo and clinic are split.
The decision to escalate is not a failure of the initial TTE. It is the protocol. Discordance between echo severity grading and clinical presentation is itself an indication for advanced imaging.
The Heart Team and the 2025 ESC/EACTS Structural Standards
The 2025 ESC/EACTS Guidelines formalized a structural requirement that has been implicit for years: a Heart Team, working in or with a Heart Valve Centre, evaluates the imaging, the clinical context, and the patient before major valve intervention decisions are made.
The Heart Team includes interventional cardiologists, cardiac surgeons, imaging specialists, and — increasingly — heart failure specialists, structural heart interventionalists, and geriatricians for older patients. The Centre provides the structural support: high-volume operators, surgical backup, multidisciplinary valve clinics, and quality monitoring aligned with the 2024 ACC/AHA Valvular and Structural Heart Disease Performance Measures.
What changed in 2025 is the positioning. The Heart Team is no longer an optional consult for borderline cases. It is the decision point for any intervention in severe valve disease where the imaging, the clinical context, or the procedural pathway is not straightforward. That includes elderly patients with frailty considerations, patients with multiple valve lesions, and patients being evaluated for transcatheter versus surgical intervention.
For the referring clinician, the practical implication is this: when you have a patient with severe VHD on echo and you're not certain about the next step, the Heart Team is the next step. The valve centre referral is the action, not a referral to one specialty over another.
Putting It Together: The Referral Checklist
The clinical pathway for valvular heart disease imaging compresses into a working checklist:
1. Order TTE first. For any suspected VHD, any change in clinical status in known VHD, and any pre-procedural assessment.
2. Confirm anatomy, grade severity, assess ventricular response. Three questions, one study.
3. Read the Level I parameters together. Peak velocity, mean gradient, and valve area for AS. Regurgitant volume, RF, EROA, and vena contracta for AR and MR.
4. Watch the LVEF. < 55% in chronic severe AR triggers surgical referral. < 50% in severe AS triggers intervention consideration. 30–60% in severe organic MR triggers intervention timing.
5. Escalate on discordance, not on repeat. TEE, CT, or MRI when TTE is non-diagnostic or disagrees with the clinical picture.
6. Refer to the Heart Team for severe VHD with intervention under consideration, especially for transcatheter candidates, elderly patients, or multi-valve disease.
TTE in. Thresholds graded. Triggers identified. Escalation pathway defined. Heart Team as the decision point. The probe starts the pathway; the guidelines structure it; the Heart Team executes it.